Research from e27, e27

Research from e27

e27 is Asia's largest Tech media platform. We cover the latest news on emerging and disruptive businesses across the region.

Private Capital Markets

<ul><li>Singapore-headquartered RNA technology company, Mirxes Holding, has completed its Series D funding round, securing US$50 million.</li><li>The round is anchored by existing and new investors, including Beijing Fupu, EDBI, Mitsui &amp; Co., NHH Venture Fund, and the Agency for Science, Technology and Research.</li><li>Mirxes Holding will use the capital to scale the adoption and penetration of its stomach cancer blood test, GASTROClear, in major Asia-Pacific markets, including Southeast Asia, China, and Japan.</li></ul>

Singapore-headquartered RNA technology company, Mirxes Holding, has completed its Series D funding round, securing US$50 million.The round is anchored by existing and new investors, including Beijing Fupu, EDBI, Mitsui &amp; Co., NHH Venture Fund, and the Agency for Science, Technology and Research.Mirxes Holding will use the capital to scale the adoption and penetration of its stomach cancer blood test, GASTROClear, in major Asia-Pacific markets, including Southeast Asia, China, and Japan.

Mirxes Lands US$50M to Take Its Cancer Early Detection Solutions to New Markets

Singapore

MiRXES Pte. Ltd. operates as a biotechnology company. The Company focuses on developing non-invasive screening tests for early detection of cancers, as well as RNA technology for cardiovascular, metabolic, and infectious diseases. MiRXES serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Mirxes Holding (MIRXES HK)

Mirxes Lands US$50M to Take Its Cancer Early Detection Solutions to New Markets

Mirxes will use the capital to scale the adoption and penetration of its stomach cancer blood test, GASTROClear, in major APAC markets

e27

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)